Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer – A rare complication
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy for non-muscle invasive bladder cancer (NMIBC) has been used as a treatment since 1976. It is effective in reducing disease recurrence and progression, with mostly self-limiting or mild side effects. Serious complications are rare and thought...
Main Authors: | Katherine Ong, John Dyer, Moira Wilson, Dickon Hayne |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-05-01
|
Series: | Urology Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214442022000158 |
Similar Items
-
Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01) -
Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01) -
Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01) -
Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: Study protocol for a randomized, controlled pilot and feasibility study
by: Sarah P. Psutka, et al.
Published: (2022-12-01) -
Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
by: Azharuddin Mohammed, et al.
Published: (2017-12-01)